Doctors from the Chinese Academy of Medical Sciences, The Ohio State University and The University of North Carolina at Chapel Hill will collaborate on research, training and best practices for IOERT treatment

Sunnyvale, California; February 13, 2008 - IntraOp Medical Corporation (OTCBB: IOPM), announced today that two North American hospitals that use the Mobetron as part of their cancer treatment protocol will welcome doctors from the Cancer Institute & Hospital, Chinese Academy of Medical Sciences (CAMS), for a scholarly exchange on intraoperative electron-beam radiation therapy (IOERT). Radiation and surgical oncologists from The Ohio State University and The University of North Carolina at Chapel Hill will embark on a long-term commitment to international education and research collaboration by sharing their facilities with their peers from CAMS for two weeks beginning on February 15, 2008.

The premier cancer research and treatment center in China, CAMS conducts more than 10,000 cancer operations each year. In one month, CAMS doctors perform more than 900 cancer surgeries. This is equivalent to the annual volume of cancer surgeries of many U.S. hospitals. CAMS installed IntraOp's Mobetron in the fall of 2007, and in doing so became the first hospital in China to offer operating room-based IOERT. While the Mobetron is currently being used by CAMS to treat China's growing number of lung cancer cases, the facility's doctors are also eager to learn how fellow surgeons and radiologists are using the Mobetron to fight other disease types, including colorectal, head and neck cancer, pancreatic cancer and breast cancer.

In order to facilitate this learning process, Don Goer, IntraOp founder and chief scientist, along with Dr. John C. Grecula, M.D., a radiation oncologist at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State, traveled to Beijing to conduct a week-long IOERT symposium for more than 150 cancer specialists at CAMS in October, 2007. Dr. Grecula presented on practical topics, such as room and patient set-up, as well as IOERT treatment options for advanced head and neck and colorectal cancers.

This symposium marked the beginning of IntraOp's commitment to bringing cutting-edge cancer centers together to continue the IOERT learning process. The CAMS doctors arrive in the United States on February 14 and will visit four hospitals that currently use the Mobetron as part of their cancer-fighting regimen.

The CAMS practitioners participating in this scholarly exchange include Dr. Tiecheng Wu, thoracic surgeon and associate professor; Dr. Qi Xue, general surgeon and associate professor; Dr. Jun Zhang, thoracic surgeon and associate professor; Dr. Minghui Li, radiation oncologist; Dr. Xiuhong Wu, medical physicist; and Jun Zhao, chief operating room nurse. On February 15, the CAMS scholars will visit The University of California at San Francisco, home of the first Mobetron, to share their experiences with the doctors on staff. They will discuss best practices for using the Mobetron, as well as how IOERT can be used to treat many types of cancer. The CAMS group will reunite with Dr. Grecula at the James Cancer Hospital and Solove Research Institute at Ohio State for additional instruction on February 17 and will complete their trip with a visit to UNC to meet and collaborate with Dr. Benjamin Calvo, associate professor and chief of the division of surgical oncology. In addition to the above centers, St. Vincent's Hospital of Indianapolis intends to support this training effort.

"I am delighted to welcome the CAMS doctors and their staff to the United States as part of our ongoing collaboration on IOERT treatment techniques," said Dr. Grecula. "CAMS is the most prestigious cancer research and treatment center in China. At the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, we share CAMS' unwavering commitment to finding inventive new ways to eradicate even the most late-stage cancers."

"The Lineberger Comprehensive Cancer Center of the University of North Carolina Chapel Hill has utilized IOERT to treat patients afflicted with breast, colorectal and soft tissue tumors for the past 7 years," said Dr. Ben Calvo, associate professor and chief divison of surgical oncology at the University of North Carolina. "The NIH funded Breast and GI S.P.O.R.E. (Special Projects of Research Excellence) grants held by our center permit significant translational science to study radiation responses of these tumors. It is our intent to develop strong clinical and basic science collaborations with our distinguished colleagues from CAMS."

"IntraOp has taken the lead in uniting the leading minds of IOERT," said Dr. Jie He, vice-dean and professor and chairman of thoracic surgery, CAMS. "We think the Mobetron and IOERT will form an integral part of our cancer program, and we thank IntraOp and all of the facilities involved in the scholarly exchange for giving us the opportunity to come together and learn from one another's IOERT techniques."

Dr. Peter Yu, IntraOp's director of Far East operations, added, "CAMS sets the standard in China for cutting-edge cancer research and treatment. Doctors from regional cancer centers in China's 30 provinces who will acquire Mobetrons in the future will travel to CAMS to learn the latest IOERT treatment options and techniques. In this regard, CAMS' Mobetron will play a vital role in IOERT training not only for CAMS physicians, but also for the hundreds of surgical and radiation oncologists who train at CAMS and then return to their own hospitals across China.

About Intraop

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.